

Company Announcement  
ASX: HPC

DATE: 28/8/2023

## Non-Executive Director Resignation

Hydration solutions company **The Hydration Pharmaceuticals Company Limited (ASX: HPC)** (“**Hydralyte North America**” or “**the Company**”) hereby advises that Ms Gretta van Riel has resigned as a Non-Executive Director of the Company, effective from the 26<sup>th</sup> of September.

The Company would like to thank Ms van Riel for her valued contribution to the strategic direction of the business, and wishes her well in her future endeavours and other business commitments.

Operationally in the year to-date, Hydralyte North America has established strong momentum with its stated strategy to generate consistent revenue growth from a lower cost base. In line with that strategy, the Company will not be looking to appoint a replacement for Ms van Riel at this time.

**-ENDS-**

**This announcement was authorised for release by the Chair of the Board of Hydralyte North America.**

For further information:

**Investors/Media**

Henry Jordan

Six Degrees Investor Relations

0431 271 538

[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)

**About Hydration Pharmaceuticals Company Limited**

The Hydration Pharmaceuticals Company Limited (HPC) distributes a leading range of electrolyte-rich tablets, liquid and powders originally developed in Australia under the Hydralyte brand. Hydralyte North America does not operate in Australia or New Zealand, where the brand is owned by Care Pharmaceuticals, but has exclusive rights to the Hydralyte brand in North and South America, Europe (excluding Turkey), China (excluding Taiwan) and Hong Kong, Current operations are focused on the United States and Canada, with headquarters in San Diego, California. HPC aims to grow its footprint in new international markets, led by an experienced management team and highly skilled Board of Directors.